Oncotarget

Meta-Analysis:

Prognostic role of tumour-associated macrophages and macrophage scavenger receptor 1 in prostate cancer: a systematic review and meta-analysis

Jian Cao, Jun Liu, Ran Xu, Xuan Zhu, Xiaokun Zhao and Bin-Zhi Qian _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:83261-83269. https://doi.org/10.18632/oncotarget.18743

Metrics: PDF 2232 views  |   HTML 3027 views  |   ?  


Abstract

Jian Cao1,3,4, Jun Liu2, Ran Xu1, Xuan Zhu1, Xiaokun Zhao1 and Bin-Zhi Qian3

1Department of Urology, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, P.R. China

2Department of Urology, The Fifth Affiliated Hospital of Xinjiang Medical University, Wulumuqi, Xinjiang 830011, P.R. China

3MRC Centre for Reproductive Health, Queen’s Medical Research Institute, Edinburgh EH16 4TJ, United Kingdom

4Current/Present address: Department of Urology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan 410013, P.R. China

Correspondence to:

Bin-Zhi Qian, email: [email protected]

Keywords: prostate cancer, tumor-associated macrophages, macrophage scavenger receptor 1, prognosis, meta-analysis

Received: September 24, 2016     Accepted: March 24, 2017     Published: June 27, 2017

ABSTRACT

Recent studies suggested that the tumour associated macrophages may be associated with prostate cancer outcome. A meta-analysis was performed to evaluate the prognostic value of tumor associated macrophages and macrophage scavenger receptor 1, marker for a subset of macrophages, by pooled hazard ratio and 95% confidence intervals from qualified studies following a systemic search. The results indicate that higher infiltration of tumor associated macrophages predicts poor overall survival (HR=1.57, 95%CI: 1.15-1.98), but not biochemical recurrence (HR=1.01, 95%CI: 0.98-1.04) or recurrence-free survival (HR=1.03, 95%CI: 0.05-2.01). In contrast, elevated level of macrophage scavenger receptor 1 was significantly associated with better recurrence-free survival (HR=3.26, 95%CI: 1.22-5.29). Thus, our analysis confirmed the prognostic value of these markers in prostate cancer outcome. We also discussed potential causes of the controversies in the literature and future research directions.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 18743